<DOC>
	<DOCNO>NCT00267319</DOCNO>
	<brief_summary>- The study primarily investigate effect copaxone fatigue treatment , compare baseline patient relapsing-remitting multiple sclerosis . - Secondary outcome measure : disability , relapse rate , quality life depression .</brief_summary>
	<brief_title>FOCUS Fatigue Outcome Copaxone USers</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>relapsingremitting Multiple Sclerosis ( MS ) , least 2 relapse previous 2 year prior copaxone interferon beta treatment , ambulant patient i.e disability score EDSS MAX 5,5 , clinically stable MS relapse free steroid free least 30 day prior start copaxone treatment hypersensitivity glatiramer acetate mannitol , pregnancy , fertile female willing use effective contraception , previous treatment copaxone The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>